

## SCHEDULES

### SCHEDULE 2

Amendment of the Human Medicines (Amendment etc.) (EU Exit) Regulations 2019

### PART 10

Amendment of Part 11 (amendment of Part 11 (Pharmacovigilance))

**133.** In regulation 166 (amendment of regulation 205 (obligations on holders in relation to public announcements))—

- (a) in paragraph (2) for “for “bodies listed” to the end substitute “after “bodies listed in paragraph (3)” insert “ where the product is subject to a UKMA(NI), UKMA(UK), THR(NI), THR(UK) or Article 126a authorisation, or the licensing authority where the product is subject to a UKMA(GB) or THR(GB), ””;
- (b) omit paragraph (3).

---

#### Commencement Information

**II** Sch. 2 para. 133 in force at 31.12.2020 immediately before IP completion day, see [reg. 1](#)

**Changes to legislation:**

There are currently no known outstanding effects for the The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020, Paragraph 133.